Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017104430> ?p ?o ?g. }
- W3017104430 endingPage "113978" @default.
- W3017104430 startingPage "113978" @default.
- W3017104430 abstract "In recent years, major developments have occurred in severe asthma management. Different asthma phenotypes and subgroups have been identified and new treatment options have become available. A total of five monoclonal antibodies are currently approved in severe asthma treatment: omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab. These drugs have been shown to reduce exacerbations and to have an oral corticosteroid-sparing effect in many severe asthma patients. However, biological treatment is not successful in all patients and should be discontinued in non-responsive patients. Treating the right patient with the right biologic, and therefore biologic response prediction, has become a major point of interest in severe asthma management. A variety of response outcomes is utilized in the different clinical trials, as well as a huge range of potential predicting factors. Also, regarding the timing of the response evaluation, there are considerable differences between studies. This review summarizes the results from studies on predicting responses and responders to biological treatment in severe asthma, taking into account clinical, functional and inflammatory parameters assessed prior to the start of treatment as well as following a few months of therapy. In addition, future perspectives are discussed, highlighting the need for more research to improve patient identification and treatment responses in the field of biological treatment in severe asthma." @default.
- W3017104430 created "2020-04-24" @default.
- W3017104430 creator A5005160219 @default.
- W3017104430 creator A5016677365 @default.
- W3017104430 creator A5034412406 @default.
- W3017104430 creator A5089962390 @default.
- W3017104430 date "2020-09-01" @default.
- W3017104430 modified "2023-10-14" @default.
- W3017104430 title "Prediction of response to biological treatment with monoclonal antibodies in severe asthma" @default.
- W3017104430 cites W1625157530 @default.
- W3017104430 cites W1683039388 @default.
- W3017104430 cites W1967215794 @default.
- W3017104430 cites W1988758075 @default.
- W3017104430 cites W1997745506 @default.
- W3017104430 cites W2000650705 @default.
- W3017104430 cites W2003904406 @default.
- W3017104430 cites W2006744847 @default.
- W3017104430 cites W2024585538 @default.
- W3017104430 cites W2028190708 @default.
- W3017104430 cites W2032546263 @default.
- W3017104430 cites W2038726642 @default.
- W3017104430 cites W2039930386 @default.
- W3017104430 cites W2040278225 @default.
- W3017104430 cites W2041896789 @default.
- W3017104430 cites W2042788227 @default.
- W3017104430 cites W2050154180 @default.
- W3017104430 cites W2058997735 @default.
- W3017104430 cites W2060763719 @default.
- W3017104430 cites W2064248794 @default.
- W3017104430 cites W2071538770 @default.
- W3017104430 cites W2074325744 @default.
- W3017104430 cites W2081124556 @default.
- W3017104430 cites W2082624887 @default.
- W3017104430 cites W2084194943 @default.
- W3017104430 cites W2095754126 @default.
- W3017104430 cites W2098276532 @default.
- W3017104430 cites W2106715003 @default.
- W3017104430 cites W2110052844 @default.
- W3017104430 cites W2117372758 @default.
- W3017104430 cites W2119046820 @default.
- W3017104430 cites W2119256134 @default.
- W3017104430 cites W2119767364 @default.
- W3017104430 cites W2121954044 @default.
- W3017104430 cites W2129649074 @default.
- W3017104430 cites W2132665714 @default.
- W3017104430 cites W2136423984 @default.
- W3017104430 cites W2138355864 @default.
- W3017104430 cites W2146963207 @default.
- W3017104430 cites W2154761796 @default.
- W3017104430 cites W2154974655 @default.
- W3017104430 cites W2161045611 @default.
- W3017104430 cites W2169228559 @default.
- W3017104430 cites W2205538181 @default.
- W3017104430 cites W2309688181 @default.
- W3017104430 cites W2314443675 @default.
- W3017104430 cites W2338443462 @default.
- W3017104430 cites W2342693354 @default.
- W3017104430 cites W2342921944 @default.
- W3017104430 cites W2370552689 @default.
- W3017104430 cites W2405917170 @default.
- W3017104430 cites W2414030569 @default.
- W3017104430 cites W2465086462 @default.
- W3017104430 cites W2471053565 @default.
- W3017104430 cites W2471110308 @default.
- W3017104430 cites W2475190422 @default.
- W3017104430 cites W2507725704 @default.
- W3017104430 cites W2511120040 @default.
- W3017104430 cites W2513258422 @default.
- W3017104430 cites W2585010481 @default.
- W3017104430 cites W2604291894 @default.
- W3017104430 cites W2606779794 @default.
- W3017104430 cites W2619633721 @default.
- W3017104430 cites W2620841583 @default.
- W3017104430 cites W2726269469 @default.
- W3017104430 cites W2755334065 @default.
- W3017104430 cites W2761520475 @default.
- W3017104430 cites W2764071025 @default.
- W3017104430 cites W2766313331 @default.
- W3017104430 cites W2767707408 @default.
- W3017104430 cites W2769218063 @default.
- W3017104430 cites W2774019602 @default.
- W3017104430 cites W2775107440 @default.
- W3017104430 cites W2790766248 @default.
- W3017104430 cites W2791719145 @default.
- W3017104430 cites W2799775149 @default.
- W3017104430 cites W2800892995 @default.
- W3017104430 cites W2801079022 @default.
- W3017104430 cites W2805002966 @default.
- W3017104430 cites W2884019861 @default.
- W3017104430 cites W2888063502 @default.
- W3017104430 cites W2899900273 @default.
- W3017104430 cites W2904416376 @default.
- W3017104430 cites W2908856481 @default.
- W3017104430 cites W2911620403 @default.
- W3017104430 cites W2913829177 @default.
- W3017104430 cites W2937418718 @default.
- W3017104430 cites W2941234997 @default.
- W3017104430 cites W2944052075 @default.